Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
26 déc. 2023 07h13 HE
|
Rayzebio, Inc.
Transaction Brings RayzeBio’s Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb’s Leading Oncology...
RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
13 nov. 2023 16h01 HE
|
Rayzebio, Inc.
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today...
RayzeBio to Participate in Upcoming Investor Conferences in November 2023
06 nov. 2023 16h05 HE
|
Rayzebio, Inc.
SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a biopharmaceutical company developing an innovative radiopharmaceutical pipeline to treat different cancers, today...
RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors
01 nov. 2023 06h00 HE
|
Rayzebio, Inc.
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today...
FDA selects RayzeBio to Participate in the Inaugural CDRP Program to Expedite Commercial Manufacturing Readiness for RYZ101 in GEP-NETs
24 oct. 2023 08h00 HE
|
Rayzebio, Inc.
SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today...
RayzeBio to Present at European Society for Medical Oncology (ESMO) Congress
18 oct. 2023 07h00 HE
|
Rayzebio, Inc.
SAN DIEGO, Oct. 18, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today...